Tay-Sachs disease and genetics
Tay-Sachs disease (TSD) is a severe genetic disorder characterized by the deficiency of the enzyme hexosaminidase A (Hex A), which is crucial for breaking down fatty substances in the brain and nerve cells. This autosomal recessive condition primarily affects children, who may appear healthy at birth but typically begin showing symptoms by six months of age. These symptoms progressively worsen, leading to developmental regression, seizures, and ultimately death, usually before the age of four. The disease has a notably higher incidence among certain ethnic groups, particularly Ashkenazi Jews, where the carrier rate is approximately 1 in 29, compared to 1 in 320,000 in the general population.
Diagnosis is often made through the observation of a characteristic "cherry-red spot" in the eye and confirmed by blood tests revealing reduced Hex A activity. While there is currently no cure for Tay-Sachs, advancements in genetic screening and counseling have enabled at-risk couples to make informed reproductive choices. The medical community continues to seek potential therapies, although current treatment focuses on palliative care to enhance the quality of life for affected children. Understanding the genetic nature of Tay-Sachs has been instrumental in reducing its incidence through effective population screening and prenatal diagnostics, providing a model for managing other genetic disorders.
Tay-Sachs disease and genetics
ALSO KNOWN AS: Hexosaminidase A deficiency; GM2-Gangliosidosis; TSD
DEFINITIONTay-Sachs disease (TSD) is a lethal disease inherited as an autosomal recessive disorder. Affected children are normal at birth, and symptoms are usually noticed by six months of age, after which they progressively worsen; the child usually dies at or before four years of age. There is no cure for this severe disorder of the nervous system, but an understanding of the genetic nature of the disorder has led to effective population screening, prenatal diagnosis, and genetic counseling.
Risk Factors
One of the interesting features of TSD, as is true of some other genetic disorders, is its variation across ethnic groups. While people of any ethnic descent can be TSD carriers, there is a greatly increased risk among people of Ashkenazi Jewish or Eastern European descent. According to 2023 statistics published by the National Library of Medicine, in the United States, Tay-Sachs occurred in about 1 in 320,000 live births among the general population. However, among Ashkenazi Jews, Jews who are of Central or Eastern European descent, the incidence was 1 in 3,500 live births, with 1 in 29 people being a carrier of the disease. Other groups with a higher incidence of TSD include French Canadians who live near the St. Lawrence River, members of the Cajun community of Louisiana, and an Amish community in Pennsylvania.
Etiology and Genetics
Tay-Sachs disease (TSD) is named after Warren Tay, an English ophthalmologist, and Bernard Sachs, an American neurologist, who first described the disorder. TSD is one of the lysosomal storage disorders, as are Hurler syndrome, Hunter syndrome, Gaucher disease, and Fabry disease. Lysosomes are organelles found in the cytoplasm of cells and contain many enzymes that digest the cell’s food and waste. TSD is caused by the lack of the hexosaminidase A (Hex A), which facilitates the breakdown of fatty substances and gangliosides in the brain and nerve cells. When Hex A is sufficiently lacking, as in TSD, gangliosides accumulate in the body and eventually lead to the destruction of the nervous system.
All forms of TSD are inherited as autosomal recessive disorders. Individuals with only one copy of the defective gene will not manifest the disease, while individuals with two copies of the gene will be afflicted with the disease. Couples in which only one partner carries the defective gene have no risk of having a baby with TSD, while couples in which both partners have the gene have a 25 percent risk of having a baby with TSD.
Symptoms
Children with TSD appear normal at birth and up to six months of age. During this time, they may show an exaggerated startle response to sound. Shortly after six months, more obvious symptoms appear. The child may show poor head control and an involuntary back-and-forth movement of the eyes. Also distinctive of TSD is a “cherry red spot” on the retina of the eye, first described by Tay, that usually appears after one year of age as atrophy of the optic nerve head occurs. The symptoms are progressive, and the child loses all the motor and mental skills developed to that point. Convulsions, increased motor tone, and blindness develop as the disease progresses. The buildup of storage material in the brain causes the head to enlarge, and brain weight may be 50 percent greater than normal at the time of death. There is no cure for TSD, and death usually occurs between two and four years of age, with the most common cause of death being pneumonia.
There are several forms of Tay-Sachs disease in addition to the classical, or infant, form already described. There is a juvenile form in which similar symptoms appear between two and five years of age, with death occurring around age fifteen. A chronic form of TSD has symptoms beginning at age five that are far milder than those of the infant and juvenile forms. Late-onset Tay-Sachs disease (LOTS) is a rare form in which there is some residual Hex A activity so that symptoms appear later in life and the disease progresses much more slowly.
Screening and Diagnosis
Screening and educational programs among at-risk groups (in particular, the Ashkenazi Jews) have been very effective. Couples with advance knowledge of their carrier status can receive genetic counseling so that they understand their risk of having a child affected with TSD.
Diagnosis of TSD often occurs when a “cherry-red” spot is noted during an eye exam. Blood testing will reveal decreased hexosaminidase A activity. The parents’ blood may be tested to determine their carrier status.
Treatment and Therapy
Unfortunately, there is no treatment available for TSD. Researchers continue to work towards some form of or enzyme replacement therapy that could slow or halt the relentless progression of TSD in an affected baby.
Therapy is aimed at providing comfort for the affected child and support for the family. The child may be made more comfortable by helping to clear accumulated mucus from the lungs via chest physiotherapy, thus improving breathing and decreasing the risk of infection. A nasogastric tube or percutaneous esophago-gastrostomy tube may be required for feeding, in order to avoid aspiration of liquids or foods into the lungs. Antiseizure medications may be necessary, and physical therapy may be provided in order to prevent joint stiffness and/or muscle contractures.
Prevention and Outcomes
Although much has been learned about the genetics of the Tay-Sachs gene and the protein deficiency that causes the disease, there is still no cure. Nevertheless, TSD provides an excellent example of how the medical community can assist a susceptible population in confronting an incurable genetic disease. The effective screening of populations at risk for TSD and prenatal detection of fetuses with TSD have served to dramatically reduce the overall incidence of this terrible disease.
Individuals who want to determine whether they carry the defective gene can undergo a blood plasma assay that identifies differences in Hex A activity. If one or both parents are not TSD carriers, then they will not be at risk of having an affected child. However, if both couples are carriers, then they have a 25 percent risk of bearing a child with TSD. Once a woman is pregnant, prenatal diagnosis (chorionic villus sampling at ten to twelve weeks of pregnancy, or at approximately fifteen to twenty weeks of pregnancy) can be used to ascertain whether the fetus has Tay-Sachs disease, allowing the couple to receive counseling regarding therapeutic pregnancy termination.
Bibliography
Ainsworth, Steve. "Tay-Sachs Disease—A Triumph from Disaster." Practice Nurse 41.3 (2011): 31–32. Print.
Bach G., J. Tomczak, N. Risch, and J. Ekstein. “Tay-Sachs Screening in the Jewish Ashkenazi Population: DNA Testing Is the Preferred Procedure.” American Journal of Medical Genetics 99 (15 Feb. 2001). Print.
Bembi, B. “Substrate Reduction Therapy in the Infantile Form of Tay-Sachs.” Neurology 66 (24 Jan. 2006). Print.
Desnick, Robert J., and Michael M. Kaback, eds. Tay-Sachs Disease. San Diego: Academic, 2001. Print.
Leavitt, J. A. “The ʻCherry Red’ Spot.” Pediatric Neurology 37 (1 July 2007). Print.
National Tay-Sachs and Allied Diseases Association. A Genetics Primer for Understanding Tay-Sachs and the Allied Diseases. Brookline: Author, 1995. Print.
Parker, James N., and Philip M. Parker, eds. The Official Parent’s Sourcebook on Tay-Sachs Disease: A Revised and Updated Directory for the Internet Age. San Diego: Icon, 2002. Print.
Ramani, Praveen Kumar, and Bindu Parayil Sankaran. Tay-Sachs Disease. StatPearls, National Library of Medicine, 25 Jan. 2023, www.ncbi.nlm.nih.gov/books/NBK564432/. Accessed 4 Sept. 2024.
"Tay-Sachs disease." MedlinePlus, 30 Sept. 2021, medlineplus.gov/genetics/condition/tay-sachs-disease/. Accessed 4 Sept. 2024.
Wenger, David, et al. "Lysosomal Storage Diseases: Heterogenous Group of Disorders." BioImpacts 3.4 (2013): 145–47. Print.
Yerramilli-Rao, Padmaja, et al. "The Natural History of Late Onset Tay-Sachs Disease." Molecular Genetics and Metabolism 105.2 (2012): S67. Print.
Zallen, Doris Teichler. Does It Run in the Family? A Consumer’s Guide to DNA Testing for Genetic Disorders. New Brunswick: Rutgers UP, 1997. Print.